The global mesenchymal stem cells market size was valued at USD 2.7 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 12.8% from 2023 to 2030. An increase in prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders coupled with rising implication of stem cells in management of these chronic conditions are anticipated to drive global mesenchymal stem cell market. In addition, increasing popularity of regenerative medicine and surge in R&D activities by biopharmaceutical companies to develop novel therapies by using mesenchymal stem cells is another factor propelling market growth forward.
The versatility of MSCs has boosted their use in therapeutic settings. Apart from the use of MSCs in regenerative medicine and tissue engineering, scientists are exploring their potential in treatment of various diseases, including cancer. Several clinical trials and studies are being conducted to test the efficacy and safety of MSCs in diseases such as graft versus host disease, cerebral palsy, systemic lupus erythematous, type1 diabetes, and rheumatoid arthritis. For instance, Mayo clinic researchers are investigating novel therapies for the management of discogenic LBP. These therapies comprise biologic agents like PRP and mesenchymal stem cells.
In addition, On June 2022, the University of Technology Sydney has developed the 3D printed system for harvesting stem cells from the bioreactors. Stem cells are used in the treatments of many diseases and injuries from diabetes and arthritis to cancer. This factor is also expected to support market expansion.
Acknowledging the profitable opportunities posed by the market, key industry participants are focused towards initiating technological collaborations to strengthen their market presence. In August 2020, NantKwest Inc. collaborated with Generate Life Sciences Co. to develop a mesenchymal stem cell-based treatment against COVID-19. In addition, in September 2021 Cynata Therapeutics Limited announced strategic partnership with Fujifilm Corporation. Under this partnership Fujifilm offered commercial and clinical production services for and supply of Cyanta’s therapeutic MSCs products.
Expanding clinical applications of mesenchymal stem cells, strengthening the pipeline of these therapies, along with intensifying market competition are some of the key aspects driving the industry expansion of MSCs. The COVID-19 outbreak has propelled the investments made in this market space. For instance, in April 2020, Canada’s The Stem Cell Network (SCN) provided funding of USD 300,000 to the project targeted towards the evaluation of optimal dosage of MSCs, to design an effective therapeutic approach to reduce the impacts of respiratory disorders associated with SARS-CoV-2 infection. Moreover, in recent years the mesenchymal stem cell therapies have been investigated for bone and related disorders, and cardiovascular disorders.
The majority of the mesenchymal stem cell applications are oriented towards research and clinical settings with comparatively lesser penetration across commercial applications. This is primarily attributed to the lack of standardized and regulated delivery of stem cell therapies; and ethical as well as safety concerns associated with human MSCs. Developments in the regulations and standardization of the mesenchymal stem cell industry are imperative to maintain market growth.
The products segment dominated the market and accounted for the largest revenue share of 78.8% in 2022. Among the products, the cells and cell lines segment has emerged as a key contributor to the segment’s revenue. Several market players are engaged in capturing untapped avenues of this market space by undertaking various initiatives such as new product development, business expansion. These players offer mesenchymal stem cells and cell lines to support the research community.
Whereas the services segment is expected to register fastest growth rate during the forecast period. Companies offering services for MSC research are anticipated to witness lucrative growth owing to increase in the number of studies and clinical applications of MSCs as potential treatment for life-threatening diseases. Large-scale laboratories have in-house facilities for different stages of workflow. However, medium- and small-scale research and academic centers prefer Contract Research Organizations (CROs) or specific service providers.
The culture and cryopreservation segment held the largest revenue share of 44.5% in 2022. The rising demand for cryopreservation services, presence of advanced healthcare infrastructure, and rising research activities in MSCs culture effectivity are anticipated to drive segment growth. For instance, in June 2020, researchers in Malaysia published a systemic review for the assessment of application of microcarriers in MSC cultures. As per the study, MSCs could proliferate in a microcarrier culture system, which further induces cell differentiation. Merck KgaA, R&D systems, and STEMCELL Technologies are some of the major companies operating in this segment.
The differentiation segment is projected to exhibit the highest CAGR of over 15.0% during 2023-2030. Companies operating in this segment offer products such as kits that support complete differentiation of human mesenchymal stem cells into osteoblasts, fat cells, cartilage cells, or bone cells. Thermo Fisher Scientific, Cyagen Biosciences, ScienCell Research Laboratories are some of the key market players providing various kits for differentiation of MSCs. The launch of serum-free and xeno-free hMSC differentiation kits has led to major advancement in this segment, thus expected to drive the segment.
The allogenic MSCs segment accounted for the higher revenue share of 56.6% in 2022. This is attributed to the high safety profile of allogeneic mesenchymal stem cells in clinical applications. Additionally, implantation of allogeneic MSCs is set to emerge as a pioneering cell-based therapeutic approach owing to the associated low immunogenicity coupled with immunosuppressive properties. These properties result in a reduced immune response, which in turn contributes to the success of allogeneic MSC implantations.
On the other hand, the use of autologous mesenchymal stem cells has undergone various advances in the past few years. The segment is expected to register a CAGR of 13.03% during 2023-2030. Various studies are being conducted using autologous MSCs for the treatment of various diseases and this is projected to offer exponential growth opportunities for the segment in coming years.
The bone marrow segment dominated the market and accounted for the largest revenue share of 24.5% in 2022. Bone marrow is a major source of isolation for mesenchymal stem cells. These cells have multiline age differentiation potential and can differentiate into bones, cartilage, tendons, fibroblasts, fat, cardiac muscle cells, and endothelial cells. The rising demand for MSCs and increasing adoption of mesenchymal stem cells in disease modeling and drug discovery are projected to drive segment growth.
Whereas MSCs derived from adipose tissues have pegged the second position in the market in terms of revenue share. The segment is expected to register a CAGR of 12.63% over the forecast period. These offer multipotent mesenchymal stem cells exhibiting several advantages across extraction, isolation, and expansion along with robust cell concentration. The unique characteristics of adipose-derived mesenchymal stem cells make the application of these cells advantageous as compared to others. Moreover, the use of autologous adipose-derived MSCs is promising for both organs damaged by disease and injury and regenerative medicine.
The cardiovascular diseases segment dominated the Mesenchymal Stem Cells (MSCs) market and accounted for the largest revenue share of 22.5% in 2022. Several pre-clinical studies have shown that the transplantation of mesenchymal stem cells improves cardiovascular repair, which has strengthened the penetration of MSCs in cardiovascular disease indications. This is also attributed to the properties of MSCs such as increasing apoptosis resistance, promoting the differentiation of myocardial cells, inhibiting fibrosis, reducing the level of inflammation, and promoting angiogenesis.
The inflammatory and immunological diseases segment held the second largest revenue share of the segment. MSCs have emerged as a promising alternative for treatment of inflammatory diseases. Several clinical trials are being conducted using MSC-based products for evaluating efficacy in treatment of inflammatory disorders. The therapeutic potential of MSCs is being evaluated in inflammatory diseases such as graft-versus-host disease, Crohn’s disease, organ fibrosis, and diabetic nephropathy.
The disease modelling application segment dominated the market and accounted for the largest revenue share of 35.1% in 2022. The use of cellular disease models with patient specific MSCs provides an ideal tool for pathological research. The mesenchymal stem cells derived from patient Induced Pluripotent Stem Cells serve as a potential disease modelling tool. The increasing number of research studies has used mesenchymal stem cell models to analyze the underlying mechanisms of chronic disorders. Moreover, MSCs are also used as models in the assessment of non-hematological mesenchymal cancers such as sarcomas, which has contributed to the dominance of this segment.
The tissue engineering application segment is set to expand at a highest CAGR of 15.89% from 2023 to 2030. Mesenchymal stem cells have emerged as a promising therapeutic approach in tissue engineering. Owing to their high capacity of expansion, self-renewal, and reduced tumorigenic capacity, these cells have widespread applications. Mesenchymal stem cell encapsulation techniques have gained immense demand in this market space in recent years.
North America dominated the market and accounted for the largest revenue share of 44.28% in 2022. A substantial number of clinical trials are underway to assess the efficacy and safety of mesenchymal stem cells as a viable treatment, for several life-threatening diseases in the U.S. Furthermore, a significant number of major companies that are engaged in the supply and commercialization of MSCs are headquartered in the North America. In addition, supportive government legislation, rising demand for innovative therapeutics, and increasing efforts from market participants to develop advanced mesenchymal stem cell therapies for managing chronic disorders. These factors have contributed to the dominance of the region in the market.
A strong research base to evaluate the implications of clinical scale manufacturing of mesenchymal stem cells coupled with improved funding programs from various public and private organizations is expected to drive the adoption of MSCs across the European countries. Countries in the Asia Pacific region are expected to create strong competitors in this space and the region is expected to expand at fastest CAGR of 14.50% during 2023-2030. The growth is accounted to huge patient base, and rising investment by market players in the region.
Several major companies are vying for a higher market share in the very competitive and fragmented mesenchymal stem cells market. Major key companies are undertaking strategic activities like mergers, acquisitions, and alliances to elevate their market position. For instance, in May 2023 Stemmatters and Pluristyx announced partnership to bolster the development of induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell banks. Some of the key players in the global mesenchymal stem cells market include:
Thermo Fisher Scientific, Inc
Cell Applications, Inc
Axol Biosciences Ltd
Cytori Therapeutics Inc
BrainStorm Cell Limited
Stemedica Cell Technologies Inc
Merck KGaA (MilliporeSigma)
Market size value in 2023
USD 3.10 Billion
Revenue forecast in 2030
USD 7.21 Billion
CAGR of 12.8% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Products and services, workflow, type, source of isolation, indication, application, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Thermo Fisher Scientific, Inc.; Cell Applications, Inc.; Axol Biosciences Ltd.; Cytori Therapeutics Inc; STEMCELL Technologies; Cyagen Biosciences.; Celprogen Inc; BrainStorm Cell Limited.; Stemedica Cell Technologies Inc; Merck KGaA (MilliporeSigma); Lonza; PromoCell GmbH
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global mesenchymal stem cells market on the basis of products and services, workflow, type, source of isolation, indication, application, and region:
Product & Services Outlook (Revenue, USD Million, 2018 - 2030)
Cells & Cell Lines
Kits, Media, & Reagents
Workflow Outlook (Revenue, USD Million, 2018 - 2030)
Cell Sourcing & Isolation
Culture & Cryopreservation
Type Outlook (Revenue, USD Million, 2018 - 2030)
Source of Isolation Outlook (Revenue, USD Million, 2018 - 2030)
Indication Outlook (Revenue, USD Million, 2018 - 2030)
Bone And Cartilage Repair
Inflammatory And Immunological Diseases
Application Outlook (Revenue, USD Million, 2018 - 2030)
Drug Development & Discovery
Stem Cell Banking
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global mesenchymal stem cells market size was estimated at USD 2.77 billion in 2022 and is expected to reach USD 3.10 billion in 2023.
b. The global mesenchymal stem cells market is expected to witness a compound annual growth rate of 12.81% from 2023 to 2030 to reach USD 7.21 billion by 2030.
b. The product segment dominated the global mesenchymal stem cells market in 2022, accounting for a revenue share of 78.8%. Among the products, mesenchymal stem cells & cell lines have emerged as a key contributors to the segment’s revenue.
b. Some of the key players in the mesenchymal stem cells market include Thermo Fisher Scientific Inc., Cell Applications Inc., Axol Biosciences Ltd.; Cytori Therapeutics Inc; STEMCELL Technologies; Cyagen Biosciences.; Celprogen Inc; BrainStorm Cell Limited.; Stemedica Cell Technologies Inc; Merck KGaA (MilliporeSigma); Lonza; PromoCell GmbH among others.
b. Key factors that are driving the mesenchymal stem cells market growth include the exponential rise in mesenchymal stem cell-based research, huge implications in the field of regenerative medicine, and the constantly evolving landscape of stem cell therapies.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.